# data[].attributes.body
The symptoms of Meningococcus can include intravascular clotting, tissue necrosis in the extremities, cardiac failure, and even death.

# data[].attributes.body
Receiving a vaccine is recommended to help prevent the infection of Meningococcus. Immunization targeting serogroups A, C, W, and Y is highly suggested for ages 11-18 years of age.

# data[].attributes.body
Neisseria Meningitidis is a serious human pathogen that is associated with Meningococcus and sometimes epidemic cerebrospinal meningitis.

# data[].attributes.body
Treatment for meningococcus is a third-generation cephalosporin such as ceftriaxone that is broad spectrum and crosses the blood-brain barrier. Patients may also have to receive treatment for shock and intravascular clotting. when treated, Meningococcus still has a morality rate of 15%.

# data[].attributes.body
N. Meningitidis commonly affects young children between 6 and 36 months, older children, and young adults between the ages of 10 and 20 years. The Vaccine is recommended to all people between the age of 11 to 18 years of age, people in high-risk populations, students, military recruits, and people who have been exposed during outbreaks.

# data[].attributes.body
Meningococcus is acquired through close contact with secretions or droplets.